Ken Griffin Merrimack Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

Call Options

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q1 2024 May 15, 2024	BUY	$13.06 - $15.0 $292,544 - $336,000	22,400 Added 77.78%	51,200 $756,000
Q4 2023 Feb 14, 2024	SELL	$12.02 - $13.41 $591,384 - $659,772	-49,200 Reduced 63.08%	28,800 $386,000
Q3 2023 Nov 14, 2023	SELL	$11.6 - $12.52 $329,440 - $355,568	-28,400 Reduced 26.69%	78,000 $961,000
Q2 2023 Aug 14, 2023	SELL	$12.02 - $13.07 $2.63 Million - $2.86 Million	-218,900 Reduced 67.29%	106,400 $1.31 Million
Q1 2023 May 15, 2023	BUY	$11.35 - $12.32 $13,620 - $14,784	1,200 Added 0.37%	325,300 $4 Million
Q4 2022 Feb 14, 2023	BUY	$3.68 - $12.51 $1.12 Million - $3.8 Million	303,700 Added 1488.73%	324,100 $3.71 Million
Q3 2022 Nov 14, 2022	BUY	$3.7 - $6.06 $31,450 - $51,510	8,500 Added 71.43%	20,400 $77,000

Others Institutions Holding MACK

# of Institutions

2

Shares Held

349

Call Options Held

0

Put Options Held

0

About MERRIMACK PHARMACEUTICALS INC

Ticker MACK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,410,200
Market Cap $203M
Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

More about MACK

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.